Greater than 97.0% as determined by analysis by RP-HPLC.
Kisspeptin-10 Synthetic is a single, non-glycosylated polypeptide chain containing 10 amino acids, having a molecular mass of 1302 Dalton and a Molecular formula of C63H83N17O14 .
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2.
Kisspeptin-10 was first discovered in 1996 and was initially named metastin due to its ability to suppress tumor metastasis. The peptide was later renamed kisspeptin in 1999 after the KISS1 gene responsible for its production . The KISS1 gene encodes the kisspeptin peptides, which are endogenous ligands for the G-protein coupled receptor 54 (GPR54), also known as KiSS1R .
Kisspeptin-10 exerts its effects by binding to GPR54 receptors located in the hypothalamus, pituitary gland, and gonads. This binding triggers a signaling cascade that stimulates the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus . GnRH then acts on the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) into the bloodstream. These hormones subsequently act on the gonads, increasing the production of sex hormones such as testosterone, estrogen, and progesterone .
Kisspeptin-10 is a critical regulator of the hypothalamic-pituitary-gonadal (HPG) axis, which is essential for reproductive function and sexual maturation. It acts as a “starter motor” for puberty by initiating the release of GnRH, leading to the production of LH and FSH, which are necessary for the development of secondary sexual characteristics and fertility . Research has shown that kisspeptin signaling is vital for maintaining reproductive health in both males and females .
Pharmaceutical versions of kisspeptin-10 are being explored for various therapeutic applications, including:
While kisspeptin-10 shows promise as a therapeutic agent, more research is needed to confirm its long-term safety and efficacy. Potential side effects include injection site pain and the risk of hormone overproduction . It is essential to consult a healthcare provider for appropriate dosage and cycle protocols .